Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...

Eli Lilly’s obesity drug Zepbound is more effective than rival Novo Nordisk’s drug Wegovy, a head-to-head trial showed, Lilly ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Eli Lilly ( LLY 0.91%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 ...

Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...

Groundbreaking results show Zepbound outperforms Wegovy, revolutionizing obesity treatment and fueling massive investor gains ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...